Schering Expands Target Validation Collaboration with Atugen to Include RNAi | GenomeWeb

NEW YORK, June 17 - Schering has extended a collaboration with Atugen of Berlin to validate drug targets associated with cancer using Atugen's KnockDown technology.

 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The Wall Street Journal reports that National Institutes of Health Director Francis Collins' response to contamination concerns at the agency might have delayed care.

The final revision of the Common Rule doesn't include the proposed change requiring consent for leftover biospecimens.

The first Reproducibility Project: Cancer Biology papers show mixed results.

In Nature this week: mobile phone-based targeted DNA sequencing, and more.